Echinacea purpurea extract inhibits LPS-induced inflammatory response by interfering with TLR4-mediated NF-κB and MAPKs signaling pathways
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Echinacea purpurea (Asteraceae family) is widely used in the European countries and the United States due to its proven immune enhancement and anti-inflammatory effects. Echinacea purpurea has been reported prevent and treat upper respiratory tract infections and common cold, but the underlying molecular mechanisms are not well understood. In the present study, we examined the anti-inflammatory effects and molecular mechanisms of Echinacea purpurea (EP) extract using lipopolysaccharide (LPS)-stimulated signal pathways in RAW264.7 cells. Our results suggest that EP extract exerts anti-inflammatory effects by down-regulating the expression of LPS-induced toll-like receptor 4 (TLR4), subsequently inhibiting the activation of nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling pathways and suppression of the release of pro-inflammatory cytokines. These results suggest that EP extract is a potential therapeutic agent for inflammatory diseases.
Abstract
Echinacea purpurea (Asteraceae family) is widely used in the European countries and the United States due to its proven immune enhancement and anti-inflammatory effects. Echinacea purpurea has been reported prevent and treat upper respiratory tract infections and common cold, but the underlying molecular mechanisms are not well understood. In the present study, we examined the anti-inflammatory effects and molecular mechanisms of Echinacea purpurea (EP) extract using lipopolysaccharide (LPS)-stimulated signal pathways in RAW264.7 cells. Our results suggest that EP extract exerts anti-inflammatory effects by down-regulating the expression of LPS-induced toll-like receptor 4 (TLR4), subsequently inhibiting the activation of nuclear factor (NF)-κB and mitogen-activated protein kinase (MAPK) signaling pathways and suppression of the release of pro-inflammatory cytokines. These results suggest that EP extract is a potential therapeutic agent for inflammatory diseases.
참고문헌 (43)
- Medzhitov R, "Innate immunity", N Engl J Med, 343(5), pp.338~344 (2000)
- 박범석, "Recognition of lipopolysaccharide pattern by TLR4complexes", Experimental and Molecular Medicine, 45(12), pp.1~9 (2013), 생화학분자생물학회
- Janeway JrCA, "Innate immune recognition", Annu Rev Immunol, 20(1), pp.197~216 (2002)
- Medzhitov R, "Innate immune recognition : mechanisms and pathways", Immunol Rev, 173, pp.89~97 (2000)
- Janeway CA, "Approaching the asymptote? Evolution and revolution in immunology", Cold Spring Harb Symp Quant Biol, 54, pp.1~13 (1989)
- Scott MG, "Interaction of cationic peptides with lipoteichoic acid and gram-positive bacteria", Infect Immun, 67(12), pp.6445~6453 (1999)
- Cheon SY, "Anti-inflammatory activity of saxifragin via inhibition of NF-κB involves caspase-1 activation", J Nat Prod, 78(7), pp.1579~1585 (2015)
- Maruthamuthu V, "Myxopyrum serratulum ameliorates airway inflammation in LPS-stimulated RAW 264.7 macrophages and OVA-induced murine model of allergic asthma", J Ethnopharmacol, 255, pp.112369~ (2020)
- Barton GM, "A calculated response : control of inflammation by the innate immune system", Journal Clin Investg, 118(2), pp.413~420 (2008)
- Lu YC, "LPS", TLR4 signal transduction pathway, 2008, pp.42(2), 145~151
- Beutler B, "Tlr4 : central component of the sole mammalian LPS sensor", Curr Opin Immunol, 12(1), pp.20~26 (2000)
- Ghosh S, "NF-κB and Rel proteins : evolutionarily conserved mediators of immune responses", Annu Rev Immunol, 16(1), pp.225~260 (1998)
- Verma IM, "Rel", NF-kappa B, Genes Dev, pp.1995, 9(22)[DOI]
- Rao KMK, "MAP kinase activation in macrophages", J Leukoc Biol, 69(1), pp.3~10 (2001)
- Kim EK, "Pathological roles of MAPK signaling pathways in human diseases", Biochim Biophys Acta Mol Basis Dis, 1802(4), pp.396~405 (2010)
- Craig WJ, "Health-promoting properties of common herbs", Am J Clin Nutr, 70(3), pp.491s~499s (1999)
- Kumar KM, "Pharmacological importance of Echinacea purpurea", Int J Pharma Bio Sci, 2(4), pp.304~314 (2011)
- Woelkart K, "Echinacea for preventing and treating the common cold", Planta Med, 74(06), pp.633~637 (2008)
- Yamada K, "A comparison of the immunostimulatory effects of the medicinal herbs Echinacea, Ashwagandha and Brahmi", J Ethnopharmaco, 137(1), pp.231~235 (2011)
- Axen A, "Gloverin, an antibacterial protein from the immune hemolymph of Hyalophora pupae", Eur J Biochem, 247(2), pp.614~619 (1997)
- Medzhitov R, "Origin and physiological roles of inflammation", Nature, 454(7203), pp.428~435 (2008)
- Zhao G, "The anti-inflammatory effects of interferon tau by suppressing NF-κB", MMP9 in macrophages stimulated with Staphylococcus aureus, 2016, pp.36(8), 516~524
- Wang T, "Preventative effect of OMZ-SPT on lipopolysaccharide-induced acute lung injury and inflammation via nuclear factor-kappa B signaling in mice", Biochem Biophys Res Commun, 485(2), pp.284~289 (2017)
- Park JR, "The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice", Oncotarget, 7(36), pp.58405~ (2016)
- Olefsky JM, "Macrophages, inflammation, and insulin resistance", Annu Rev Physiol, 72, pp.219~246 (2010)
- Surh YJ, "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals : down-regulation of COX-2 and iNOS through suppression of NF-κB activation", Mutat Res-Fundam Mol Mech Mutagen, 480, pp.243~268 (2001)
- Gil A, "Altered signalling and gene expression associated with the immune system and the inflammatory response in obesity", Br J Nutr, 98(S1), pp.S121~S126 (2007)
- Zhimin L, "Degradation of activated protein kinases by ubiquitination", Annu Rev Biochem, 78, pp.435~475 (2009)
- Weinstein SL, "Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages", J Biol Chem, 267(21), pp.14955~14962 (1992)
- Sanghera JS, "Activation of multiple proline-directed kinases by bacterial lipopolysaccharide in murine macrophages", J Immunol, 156(11), pp.4457~4465 (1996)
- Swantek JL, "Jun N-terminal kinase", stress-activated protein kinase (JNK, SAPK, pp.Mol Cell Biol, 1997[DOI]
- Chen CC, "p38 but not p44", 42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages, 1999, pp.55(3), 481~488
- Arthur JSC, "Mitogen-activated protein kinases in innate immunity", Nat Rev Immunol, 13(9), pp.679~692 (2013)
- Roget K, "IκB kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400", Mol Cell Biol, 32(22), pp.4684~4690 (2012)
- Lu YC, "LPS", TLR4 signal transduction pathway, 2008, pp.42(2), 145~151
- Poltorak A, "Defective LPS signaling in C3H", HeJ and C57BL, Science, pp.1998, 282(5396)[DOI]
- Qian Y, "IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFκB", J Biol Chem, 276(45), pp.41661~41667 (2001)
- Baud V, "Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain", Genes Dev, 13(10), pp.1297~1308 (1999)
- Cao Z, "TRAF6 is a signal transducer for interleukin-1", Nature, 383(6599), pp.443~446 (1996)
- Lomaga MA, "TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling", Genes Dev, 13(8), pp.1015~1024 (1999)
- Jadhav T, "Identification of a consensus site for TRAF6", p62 polyubiquitination, 2008, pp.371(3), 521~524
- Yang K, "The coiled-coil domain of TRAF6 is essential for its auto-ubiquitination", Biochem Biophys Res Commun, 324(1), pp.432~439 (2004)
- Chiu YH, "Ubiquitin in NF-κB Signaling", Chem Rev, 109(4), pp.1549~1560 (2009)
